Trevi Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 25
- Market Cap
- $211.2M
- Introduction
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.
Positive Buy Rating on Viking Therapeutics Driven by Promising VK2735 Program Advances
Viking Therapeutics (VKTX) received a Buy rating from Stifel Nicolaus analyst Annabel Samimy, citing promising advancements in its VK2735 programs. The Phase 2 VENTURE study for oral VK2735 targets obesity with potential for success, while the injectable version is set for Phase 3 trials in 2025. Viking's dual-format strategy enhances market appeal. Morgan Stanley also maintains a Buy rating with a $105 target.
Promising Clinical Results and Market Potential Drive Buy Rating for Oculis Holding
Stifel Nicolaus analyst Annabel Samimy initiated a Buy rating for Oculis Holding (OCS), citing promising clinical results of OCS-05 for acute optic neuritis treatment. The drug showed significant improvements in visual outcomes and safety, with FDA clearance for further trials. H.C. Wainwright also reiterated a Buy rating with a $30 target.
PureTech sees success in Phase IIb Pulmonary Fibrosis trial
PureTech's Phase IIb trial of deupirfenidone met endpoints, slowing lung degeneration in IPF patients. The trial evaluated 550mg and 825mg doses over 26 days, with the high dose showing superior efficacy in slowing lung function decline compared to placebo. The company aims to establish deupirfenidone as a new standard of care for IPF.
Related Clinical Trials:
Enrollment hits 75% for Phase 2b clinical trial of Haduvio for IPF
Trevi Therapeutics' Phase 2b CORAL trial for Haduvio in IPF patients with chronic cough has reached 75% enrollment. The trial continues to recruit 160 patients across 10 countries, with top-line data expected in H1 2025. Haduvio, an oral nalbuphine extended-release formulation, aims to reduce cough frequency and improve quality of life.
Nalbuphine Shows Breakthrough Abuse Resistance in Key Clinical Study
Trevi Therapeutics announces positive results from a human abuse potential study of oral nalbuphine, showing statistically significant lower 'Drug Liking' for clinical doses (81mg and 162mg) compared to 6mg IV butorphanol.
Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study
Trevi Therapeutics announces positive results from a human abuse potential study of oral nalbuphine, showing statistically significant lower 'Drug Liking' for clinical doses (81mg and 162mg) compared to 6mg IV butorphanol.
Roflumilast cream 0.15% addresses unmet needs of adults, children with atopic dermatitis
Roflumilast cream 0.15% showed high efficacy in treating mild to moderate atopic dermatitis in patients aged 6 years and older, with more patients achieving a validated IGA-AD score of 0/1 and minimal application site irritation.
Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences
Trevi Therapeutics to attend investor and medical conferences in Oct-Nov, presenting Haduvio™ for chronic cough in IPF and RCC.
© Copyright 2025. All Rights Reserved by MedPath